Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Plus I have invested in many biotech stocks, it is nice to have a CEO come out and talk to the shareholders. it is a refreshing change as opposed to just talking to IR that is clueless anyways. The CEO is nice enough to respond to questions.
Added more shares today I think this .07 cent share price is way too low and undervalued. For a company that's in a couple of phase 2 trials we should be at least at $200 mil market cap. I think that the launch of Lympro under CLIA will give us the boost we need. Also a partner would boost share price as well for AMBS
yes this is just the beginning I thought I saw on "flyonthewall" that Rxi management was supposed to be meeting up with Roth Capital tomorrow Wednesday April 23, 2014. We shall see if we get additional capital for the company. Exciting times ahead for those who were patient.
RXI Pharmaceuticals enters into agreement with Lincoln Park Capital to Purchase $20 million dollars worth of RXI stock over a 30 month period to help fund ophthalmology pipeline. Lincoln Park has already bought 500,000 shares at $4 per share and will continue to buy higher sequentially. http://investors.rxipharma.com/file.aspx?IID=4418218&FID=23303595
Tomorrow is the meeting with Roth Capital. maybe more private placement money.
Allergan (AGN) deal bodes well for Rxi Pharmaceuticals since they both deal with dermatological drugs. Rxi's drug RXI-109 is for anti-scarring.
Good SA article on Sangamo " Sangamo's Technology Can Possibly Advance New Treatments For Patients With HIV"
Talks about the future prospects of the HIV compound and the ability to manipulate genes.
Already cast my vote for Amarantus. I will do this everyday! Everyone pass it along! http://convention.bio.org/buzzofbio/voting.aspx
I think they should wait to announce the launch of LYmpro get the share price to at least .50 .60 cents then uplist. As it stands now at .07 per share they would have to do a 1 for 75 reverse split to get to around $5.25 per share.
I think it is best to wait to see all catalysts before Lympro Launch and then Lympro Launch itself before thinking of uplisting. That is of course if the price goes up on its own to .50 cents per share then even better.
People need to be patient, Lympro is expected to launch in 2nd half 2014. I think people should wait for the catalysts to materialize more instead of complaining. I think the Lympro launch will be a game changer because of the early revenue coming in. Which in turn should raise the share price. Plus there are plenty of other catalysts on the way coming up. People need more patience IMO!
Some people just don't understand the importance of Lympro. The accurate reading of patients with Alzheimer's disease is most wanted by big pharma companies. This is because the Alzheimer's trials run by big pharma fail the trials because there are 30% of patients that don't even have the Alzheimer's Disease. That means that with Lympro these big pharmaceutical companies can close to accurately increase enrollment numbers at an earlier time frame. Partnership with Lympro, and subsequent launch and this stock will take off.
Good article talking about today's news for Sarepta Therapeutics " Sarepta Pushes Back, Getting The Go Ahead To File An NDA For Eteplirsen By The End of 2014" http://www.biotechpicklist.com/sarepta-pushes-back-getting-the-go-ahead-to-file-an-nda-for-eteplirsen-by-the-end-of-2014/
I keep telling people Lympro is the driving force behind the AMBS stock. Once news of partnership for Lympro, or launch of Lympro and this stock will take off I'm patient.
Good to see AMBS got the 10-k out maybe we can see a nice move up today for shareholders.
That's because the 10-k means nothing in the grand scheme of things. Can the share price decline by one or 2 more pennies? Yes it can, so what? The key is Lympro launch and partnership with lympro that will drive up the share price above and beyond anyways so why are you worried about a few pennies now?
I think the stock just needs a good catalyst to get it moving. The trial results may or may not move it because they are early clinical trial results. But I believe that Lympro launch in 2nd half 2014 will definitely move the needle big time, especially with a big pharma partnership.
If the company is on time and is able to launch Lympro 2nd half 2014 I think the share price should rise considerably. That's not even including if AMBS obtains a partnership to launch the product then it will be even better. Good luck to all!
As I have mentioned in a previous posting the new directors and members of management come from Pharmacyclics, Novartis, and Johnson and Johnson. I have no doubt that they believe good things will come for this company to get on board so early.
I agree with everything you have stated. Also besides the science of companies I also look at management. Was it bad timing they changed CFO's 2 weeks before the 10-k was due? yes it was , but the new guy has to go through an entire year's book in just under 2 weeks. Even though the other CFO went through it, the new guy has to sign his name off on that work. So he wants to make sure what he is signing is in good order nothing wrong with that.
In terms of management the last few months they have brought on board some good people. The new board of directors, management have come from good companies. Some of the big pharma the new employees for AMBS have come from Pharmacyclics, Johnson and Johnson, and Novartis. The CEO had to entice those big executives with either big money or good science to get them to come on aboard on a stock that trades at .08 cents on the OTC. Regardless these executives came on board and they see a change in research on alzheimer's disease with Lympro and MANF.
I guarantee there will be a partnership on Lympro because from what I understand the big pharmaceutical companies that fail Alzheimer's trials do so not because their compound doesn't work but 30% of the patients enrolled skew the data because they don't even have alzheimer's disease. With an accurate test "Lympro" it may be possible to get more accurate data on who really has Alzheimer's or not. So in closing I have bought my shares and I'm ready for a long term story that will continue to be played throughout many years.
I have a huge holding now of AMBS and I am definitely long term. I have invested in another company that used to trade on the OTC that is biotech but now trades on the NASDAQ RXII (Rxi Pharmaceuticals) and I believe like it AMBS will be a long term hold.
To people complaining about the uplisting I have a different approach that may or may not happen but that I would like to see. I would prefer if the company waits till the stock price rises on its own then do a reverse stock split if need be. Even better I would like to see the share price rise on its own without a reverse split. Anyways I like the fact that the company is attempting to launch Lympro diagnostic testing as a means for generating revenue now while developing other products in the clinic.
People be tripping IMO, all is well company will file the document and everyone will be on there merry way to buying more shares of AMBS. The sky is not falling!
Today April 17th from FLYONTHEWALL news " http://www.theflyonthewall.com/permalinks/entry.php/RXIIid1994787/RXII-RXi-Pharmaceuticals-management-to-meet-with-Roth-Capital"
RXi Pharmaceuticals management to meet with Roth Capital
Meeting to be held in Boston on April 23 hosted by Roth Capital.
yes we need an update somehow, companies shouldn't be filing late. Anyways I still believe in the Science of AMBS and the pipeline itself, but the late filing is inexcusable unless there is some other news we don't know.
Another CTO (Confidential Treatment Order) was just filed! Seems partnership talks is ongoing IMO. Also they are keeping hush on news lately, something big is coming up for RXII!
New SA article bearish on Prana Biotechnology http://seekingalpha.com/article/2141193-prana-biotechnology-is-still-a-short-after-recent-alzheimers-failure
Good SA article instablog on ATHX check it out! http://seekingalpha.com/instablog/1058124-long-term-bio/2788143-athersys-catalysts-that-can-increase-share-price-by-200-percent-in-2014
Because biotech has been selling off the last 2 weeks probably sparked by that Gilead science news that hep c drug would cost $84,000 per treatment. So all high flyers sold off ARWR, TKMR, ALNY,PCYC, Biogen Idec, etc. but today was a nice recovery for biotechs. Relax though RXII is a good long term name don't worry about these types of movements!
A good article on SA for Epizyme! Enjoy the read! http://seekingalpha.com/instablog/1058124-long-term-bio/2727383-epizyme-tackling-genetically-defined-cancers-one-step-at-a-time
Good SA article instablog about Tekmira and other RNAi companies! http://seekingalpha.com/instablog/1058124-long-term-bio/2743423-three-rnai-companies-worth-watching-in-2014
Good SA article on ARWR check it out! http://seekingalpha.com/instablog/1058124-long-term-bio/2743423-three-rnai-companies-worth-watching-in-2014
Good SA article on Three RNAi companies check it out! http://seekingalpha.com/instablog/1058124-long-term-bio/2743423-three-rnai-companies-worth-watching-in-2014
Rxi will be presenting at 3 presentations coming up in March as posted by this press release. I found one of them the ocular disease conference may possibly show preclinical results for one of the eye indications we will have to wait and see. But the other presentations will have poster presentations for RXI-109. Anyways in the coming weeks we should get the phase 2a keloid trial starting Press release, and possibly the private dilution the CEO was talking about where 4 funds are interested in buying RXII shares on the open market to help advance the ophthalmology pipeline.
http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-upcoming-presentations-110200892.html
Key Notes from ROTH presentation new info!
1. Four big funds have expressed interest in buying RXII shares at current market prices so that the company can advance its ophthalmology pipeline! The Board is currently in talks/deciding to go this route
2. Rxi in process of getting an additional phase 2 compound to the pipeline
3. Rxi in process of getting another patent for their technology added, probably bevasirinib patent protection
4. Middle of the year in 2014 we will see results of phase 2 hypertrophic scars midpoints 3 months after results. So no guess by CEO but I'm assuming may/june probably - may include pictures of placebo/RXI-109 to show difference
5. Macular degeneration has crowded space, but Rxi's sd-rxRNA would target both VEGF for gene knockdown and CTGF to heal wound of eye. Basically would accomplish both - two birds with one stone
6. Rxi in process of testing lucentis current therapy and combining it with RXI-109
7. PVR just need GLP toxicity study then RXII can file IND in 2nd half 2014 for PVR indication
8. More testing needed but close in silencing retinoblastoma for eye cancer in children under age 15
Things are looking good if anyone else has anything to add then please do so.
New SA article On Opexa Therapeutics that I wrote! Enjoy! http://seekingalpha.com/article/2078363-opexa-therapeutics-a-long-term-perspective-for-price-appreciation
I found a good article that debunks Adam F. Article from the Street about Rexahn. I think it is a good article that explains why the bear theory is flawed. http://www.biotechpicklist.com/why-im-bullish-for-rexahn-pharmaceuticals-in-march/
Someone mentioned this to me so it seems RXII has started the phase 2a for keloid removal trial shown here at clinical trials website http://clinicaltrials.gov/ct2/show/NCT02079168
We probably will get PR next week before presentation IMO!
Also a nice article talking about Rxi Pharmaceutical's new patent http://www.biotechpicklist.com/rxi-pharmaceuticals-receives-key-patent-for-fibrotic-treatments/
Yep another good step for RXII key patent relating to fibrotic disorders. This is big folks! Liver fibrosis/liver disease can carry a market value of $5 to $6 billion dollars. This is huge folks! http://finance.yahoo.com/news/rxi-pharmaceuticals-granted-key-patent-120200176.html
Rxi Pharmaceuticals to Present at the 26th Annual ROTH Conference! http://finance.yahoo.com/news/rxi-pharmaceuticals-present-26th-annual-120200092.html
yes everytime RXII presents at a presentation they like to report a catalyst (news) before the presentation. so come Monday we can expect either the trial start of phase 2a keloid removal trial, or phase 2a hypertrophic scar results IMO. Good luck to all of us long term holders on Monday March 3rd!
Yep Monday is the Wall sTreet analyst forum presentation. Expect news though before the presentation that's how RXII likes to release their news.